<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href="http://www.blogger.com/styles/atom.css" type="text/css"?><feed xmlns='http://www.w3.org/2005/Atom' xmlns:openSearch='http://a9.com/-/spec/opensearchrss/1.0/' xmlns:georss='http://www.georss.org/georss' xmlns:gd='http://schemas.google.com/g/2005' xmlns:thr='http://purl.org/syndication/thread/1.0'><id>tag:blogger.com,1999:blog-4843766896928294571</id><updated>2012-02-16T07:07:49.957-08:00</updated><category term='Clinical Research'/><category term='Regulatory inspections and approvals'/><category term='AXIS Clinicals Latina SA de CV Mexico'/><title type='text'>AXIS Clinicals</title><subtitle type='html'></subtitle><link rel='http://schemas.google.com/g/2005#feed' type='application/atom+xml' href='http://axisclinicals.blogspot.com/feeds/posts/default'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4843766896928294571/posts/default?max-results=100'/><link rel='alternate' type='text/html' href='http://axisclinicals.blogspot.com/'/><link rel='hub' href='http://pubsubhubbub.appspot.com/'/><author><name>AXIS Clinicals</name><uri>http://www.blogger.com/profile/13842254577550770182</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='12' src='http://2.bp.blogspot.com/-Huq8MOoRHMY/TbFbTjKswzI/AAAAAAAAAAM/yvDOahLahX4/s220/Axis_logo.jpg'/></author><generator version='7.00' uri='http://www.blogger.com'>Blogger</generator><openSearch:totalResults>3</openSearch:totalResults><openSearch:startIndex>1</openSearch:startIndex><openSearch:itemsPerPage>100</openSearch:itemsPerPage><entry><id>tag:blogger.com,1999:blog-4843766896928294571.post-7390276004354568878</id><published>2012-01-25T01:02:00.000-08:00</published><updated>2012-01-25T01:02:07.480-08:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='AXIS Clinicals Latina SA de CV Mexico'/><title type='text'>AXIS Clinicals introduced the Mexico facility to boost global presence</title><content type='html'>&lt;div dir="ltr" style="text-align: left;" trbidi="on"&gt;&lt;div class="MsoBodyText" style="margin: 0in 0in 6pt;"&gt;&lt;span style="font-family: Calibri;"&gt;Mexico City, Mexico - AXIS Clinicals widen its global footprint with starting the Mexico facility. &lt;/span&gt;&lt;/div&gt;&lt;div class="MsoBodyText" style="margin: 0in 0in 6pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div class="MsoBodyText" style="margin: 0in 0in 6pt;"&gt;&lt;span style="font-family: Calibri;"&gt;AXIS Clinicals Latina SA de CV, the one of the largest infrastructure for the Bioequivalence / Bioavailability facility in Mexico which houses 138 beds for the clinical unit and planning for 4 LC-MS/MS as the Phase I expansion. This facility has been designed using GCP and GLP requirements to meet the Global Regulatory Standards. &lt;/span&gt;&lt;/div&gt;&lt;br /&gt;&lt;span style="font-family: &amp;quot;Calibri&amp;quot;, &amp;quot;sans-serif&amp;quot;; mso-ansi-language: EN-US; mso-bidi-font-family: &amp;quot;Times New Roman&amp;quot;; mso-bidi-language: AR-SA; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-fareast-theme-font: minor-latin;"&gt;AXIS Clinicals Latina SA de CV received the facility approval in June 2011 for Clinical and Bionalytical facility from Cofepris, the Mexican Regulatory Agency.&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;span style="font-family: &amp;quot;Calibri&amp;quot;, &amp;quot;sans-serif&amp;quot;; mso-ansi-language: EN-US; mso-bidi-font-family: &amp;quot;Times New Roman&amp;quot;; mso-bidi-language: AR-SA; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-fareast-theme-font: minor-latin;"&gt;The Bioanalytical Laboratory is equipped with the high-end instrumentation with dedicated areas as well-equipped sample processing zone, special precaution area where the controlled conditions will be maintained for the project specific requirement.&amp;nbsp;&amp;nbsp; &lt;/span&gt;&lt;br /&gt;&lt;div class="MsoBodyText" style="margin: 0in 0in 6pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div class="MsoBodyText" style="margin: 0in 0in 6pt;"&gt;P. Sarath Chandra Reddy, Managing Director mentions “Mexico BA / BE business is an important pie of our strategic expansion which will ensure the global drug development support for our business partners.”&lt;/div&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4843766896928294571-7390276004354568878?l=axisclinicals.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://axisclinicals.blogspot.com/feeds/7390276004354568878/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://axisclinicals.blogspot.com/2012/01/axis-clinicals-introduced-mexico.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4843766896928294571/posts/default/7390276004354568878'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4843766896928294571/posts/default/7390276004354568878'/><link rel='alternate' type='text/html' href='http://axisclinicals.blogspot.com/2012/01/axis-clinicals-introduced-mexico.html' title='AXIS Clinicals introduced the Mexico facility to boost global presence'/><author><name>AXIS Clinicals</name><uri>http://www.blogger.com/profile/13842254577550770182</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='12' src='http://2.bp.blogspot.com/-Huq8MOoRHMY/TbFbTjKswzI/AAAAAAAAAAM/yvDOahLahX4/s220/Axis_logo.jpg'/></author><thr:total>0</thr:total><georss:featurename>Mexico City, Distrito Federal, Mexico</georss:featurename><georss:point>19.4326077 -99.13320799999997</georss:point><georss:box>19.160787699999997 -99.34520699999997 19.7044277 -98.92120899999996</georss:box></entry><entry><id>tag:blogger.com,1999:blog-4843766896928294571.post-2148197145118770418</id><published>2012-01-21T04:00:00.000-08:00</published><updated>2012-01-21T04:00:59.041-08:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='Regulatory inspections and approvals'/><title type='text'>AXIS Clinicals : Summary of regulatory inspections and approvals</title><content type='html'>&lt;div dir="ltr" style="text-align: left;" trbidi="on"&gt;&lt;div style="layout-grid-mode: char;"&gt;&lt;b&gt;&lt;span style="color: #0070c0; font-family: &amp;quot;Verdana&amp;quot;, &amp;quot;sans-serif&amp;quot;;"&gt;AXIS Clinicals facility has been successfully audited &amp;amp;/or accredited by US FDA, UK MHRA, Brazilian ANVISA, India (DCGI), AFSSAPS,&amp;nbsp;NABL and ISO 9001:2000. &lt;/span&gt;&lt;/b&gt;&lt;span style="color: #0070c0; font-family: &amp;quot;Verdana&amp;quot;, &amp;quot;sans-serif&amp;quot;;"&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class="MsoNormal" style="layout-grid-mode: char; margin: 0in 0in 0pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div class="MsoNormal" style="layout-grid-mode: char; margin: 0in 0in 0pt;"&gt;&lt;span style="color: black; font-family: &amp;quot;Verdana&amp;quot;, &amp;quot;sans-serif&amp;quot;; font-size: 12pt;"&gt;We would like to provide you the updates for the audits&lt;/span&gt;&lt;/div&gt;&lt;div class="MsoNormal" style="layout-grid-mode: char; margin: 0in 0in 0pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;ul style="margin-top: 0in;" type="disc"&gt;&lt;li class="MsoNormal" style="color: black; layout-grid-mode: char; margin: 0in 0in 0pt; mso-list: l0 level1 lfo1; tab-stops: list .5in;"&gt;&lt;strong&gt;&lt;span style="font-family: &amp;quot;Verdana&amp;quot;, &amp;quot;sans-serif&amp;quot;; font-size: 12pt; font-weight: normal; mso-fareast-font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;8 US&amp;nbsp;FDA Audits&lt;/span&gt;&lt;/strong&gt;&lt;span style="font-family: &amp;quot;Verdana&amp;quot;, &amp;quot;sans-serif&amp;quot;; font-size: 12pt; mso-fareast-font-family: &amp;quot;Times New Roman&amp;quot;;"&gt; (recent audit in October 2011) &lt;/span&gt;&lt;/li&gt;&lt;li class="MsoNormal" style="color: black; layout-grid-mode: char; margin: 0in 0in 0pt; mso-list: l0 level1 lfo1; tab-stops: list .5in;"&gt;&lt;strong&gt;&lt;span style="font-family: &amp;quot;Verdana&amp;quot;, &amp;quot;sans-serif&amp;quot;; font-size: 12pt; font-weight: normal; mso-fareast-font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Recently completed US FDA audits with&lt;/span&gt;&lt;/strong&gt;&lt;b&gt;&lt;span style="font-family: &amp;quot;Verdana&amp;quot;, &amp;quot;sans-serif&amp;quot;; font-size: 12pt; mso-fareast-font-family: &amp;quot;Times New Roman&amp;quot;;"&gt; &lt;/span&gt;&lt;/b&gt;&lt;strong&gt;&lt;span style="font-family: &amp;quot;Verdana&amp;quot;, &amp;quot;sans-serif&amp;quot;; font-size: 12pt; font-weight: normal; mso-fareast-font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;'NO'&amp;nbsp;483’s&lt;/span&gt;&lt;/strong&gt;&lt;span style="font-family: &amp;quot;Verdana&amp;quot;, &amp;quot;sans-serif&amp;quot;; font-size: 12pt; mso-fareast-font-family: &amp;quot;Times New Roman&amp;quot;;"&gt; &lt;/span&gt;&lt;/li&gt;&lt;li class="MsoNormal" style="color: black; layout-grid-mode: char; margin: 0in 0in 0pt; mso-list: l0 level1 lfo1; tab-stops: list .5in;"&gt;&lt;span style="font-family: &amp;quot;Verdana&amp;quot;, &amp;quot;sans-serif&amp;quot;; font-size: 12pt; mso-fareast-font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Turkey Regulatory Audit (Dec 2011) &lt;/span&gt;&lt;/li&gt;&lt;li class="MsoNormal" style="color: black; layout-grid-mode: char; margin: 0in 0in 0pt; mso-list: l0 level1 lfo1; tab-stops: list .5in;"&gt;&lt;span style="font-family: &amp;quot;Verdana&amp;quot;, &amp;quot;sans-serif&amp;quot;; font-size: 12pt; mso-fareast-font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/span&gt;&lt;span style="font-family: &amp;quot;Verdana&amp;quot;, &amp;quot;sans-serif&amp;quot;; font-size: 12pt; mso-fareast-font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;UK&amp;nbsp;MHRA audit with NO findings / minor observation (Recent audit Oct 2011) &lt;/span&gt;&lt;/li&gt;&lt;li class="MsoNormal" style="color: black; layout-grid-mode: char; margin: 0in 0in 0pt; mso-list: l0 level1 lfo1; tab-stops: list .5in;"&gt;&lt;span style="font-family: &amp;quot;Verdana&amp;quot;, &amp;quot;sans-serif&amp;quot;; font-size: 12pt; mso-fareast-font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;France&amp;nbsp;AFSSAPS audit &lt;/span&gt;&lt;/li&gt;&lt;li class="MsoNormal" style="color: black; layout-grid-mode: char; margin: 0in 0in 0pt; mso-list: l0 level1 lfo1; tab-stops: list .5in;"&gt;&lt;span style="font-family: &amp;quot;Verdana&amp;quot;, &amp;quot;sans-serif&amp;quot;; font-size: 12pt; mso-fareast-font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/span&gt;&lt;span style="font-family: &amp;quot;Verdana&amp;quot;, &amp;quot;sans-serif&amp;quot;; font-size: 12pt; mso-fareast-font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Brazil&amp;nbsp;ANVISA – 3 successful audits &lt;/span&gt;&lt;/li&gt;&lt;li class="MsoNormal" style="color: black; layout-grid-mode: char; margin: 0in 0in 0pt; mso-list: l0 level1 lfo1; tab-stops: list .5in;"&gt;&lt;span style="font-family: &amp;quot;Verdana&amp;quot;, &amp;quot;sans-serif&amp;quot;; font-size: 12pt; mso-fareast-font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;ISO 900:2000 &lt;/span&gt;&lt;/li&gt;&lt;li class="MsoNormal" style="color: black; layout-grid-mode: char; margin: 0in 0in 0pt; mso-list: l0 level1 lfo1; tab-stops: list .5in;"&gt;&lt;span style="font-family: &amp;quot;Verdana&amp;quot;, &amp;quot;sans-serif&amp;quot;; font-size: 12pt; mso-fareast-font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;NABL&amp;nbsp;approval for Clinical Investigational Unit &lt;/span&gt;&lt;/li&gt;&lt;li class="MsoNormal" style="color: black; layout-grid-mode: char; margin: 0in 0in 0pt; mso-list: l0 level1 lfo1; tab-stops: list .5in;"&gt;&lt;span style="font-family: &amp;quot;Verdana&amp;quot;, &amp;quot;sans-serif&amp;quot;; font-size: 12pt; mso-fareast-font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Product approvals (for sponsors) from Health Canada, WHO, AFSSAPS, US FDA, Europe, Australia, Brazil &amp;amp;&amp;nbsp;DCGI Regulatory Agencies&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;div class="MsoNormal" style="color: black; layout-grid-mode: char; margin: 0in 0in 0pt; mso-list: l0 level1 lfo1; tab-stops: list .5in;"&gt;&lt;span style="font-family: &amp;quot;Verdana&amp;quot;, &amp;quot;sans-serif&amp;quot;; mso-fareast-font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;span style="color: blue; font-family: Verdana, sans-serif;"&gt;&lt;strong&gt;For more updates, please click on &lt;/strong&gt;&lt;/span&gt;&lt;a href="http://www.axisclinicals.com/"&gt;&lt;span style="color: magenta; font-family: Verdana, sans-serif;"&gt;&lt;strong&gt;www.axisclinicals.com&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;span style="color: blue; font-family: Verdana, sans-serif;"&gt;&lt;strong&gt; or call on +91 (40) 4040 8044&amp;nbsp;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class="MsoNormal" style="color: black; layout-grid-mode: char; margin: 0in 0in 0pt; mso-list: l0 level1 lfo1; tab-stops: list .5in;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4843766896928294571-2148197145118770418?l=axisclinicals.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://axisclinicals.blogspot.com/feeds/2148197145118770418/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://axisclinicals.blogspot.com/2012/01/axis-clinicals-summary-of-regulatory.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4843766896928294571/posts/default/2148197145118770418'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4843766896928294571/posts/default/2148197145118770418'/><link rel='alternate' type='text/html' href='http://axisclinicals.blogspot.com/2012/01/axis-clinicals-summary-of-regulatory.html' title='AXIS Clinicals : Summary of regulatory inspections and approvals'/><author><name>AXIS Clinicals</name><uri>http://www.blogger.com/profile/13842254577550770182</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='12' src='http://2.bp.blogspot.com/-Huq8MOoRHMY/TbFbTjKswzI/AAAAAAAAAAM/yvDOahLahX4/s220/Axis_logo.jpg'/></author><thr:total>0</thr:total><georss:featurename>Miyapur, Hyderabad, Andhra Pradesh, India</georss:featurename><georss:point>17.49400243815375 78.35399866104126</georss:point><georss:box>17.47723293815375 78.32972516104125 17.51077193815375 78.37827216104127</georss:box></entry><entry><id>tag:blogger.com,1999:blog-4843766896928294571.post-6857503923908286273</id><published>2011-05-04T23:15:00.001-07:00</published><updated>2011-05-04T23:15:13.611-07:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='Clinical Research'/><title type='text'>AXIS Clinicals Limited</title><content type='html'>&lt;div dir="ltr" style="text-align: left;" trbidi="on"&gt;&lt;strong&gt;AXIS Clinicals Limited &lt;/strong&gt;is one of the most experienced and fastest growing Clinical Research Organization incorporated in September 2004. &lt;br /&gt;&lt;br /&gt;Our state-of-the-art facilities houses 500+ dedicated full-time professionals to ensure the quick turn around time with high quality. Our facilities are accredited by DCGI (Drugs Controller General – India), NABL (National Accreditation Board for Testing and Calibration Laboratories - ISO 15189:2003) and inspected by US-FDA, UK-MHRA, Brazil-ANVISA and France –AFSSAPS and conforms to ICH and CDSCO-GCP &amp;amp; GLP Guidelines. &lt;br /&gt;&lt;br /&gt;Within short span, we have achieved the milestone of completing 1200+ clinical studies, 300+ ANDA study completions and 50+ product approvals from various regulatory agencies. &lt;br /&gt;&lt;br /&gt;Ten plus (10+) regulatory audits from global competent authorities is testament to our professionalism and dedication to quality studies. &lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/4843766896928294571-6857503923908286273?l=axisclinicals.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://axisclinicals.blogspot.com/feeds/6857503923908286273/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://axisclinicals.blogspot.com/2011/05/axis-clinicals-limited.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/4843766896928294571/posts/default/6857503923908286273'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/4843766896928294571/posts/default/6857503923908286273'/><link rel='alternate' type='text/html' href='http://axisclinicals.blogspot.com/2011/05/axis-clinicals-limited.html' title='AXIS Clinicals Limited'/><author><name>AXIS Clinicals</name><uri>http://www.blogger.com/profile/13842254577550770182</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='12' src='http://2.bp.blogspot.com/-Huq8MOoRHMY/TbFbTjKswzI/AAAAAAAAAAM/yvDOahLahX4/s220/Axis_logo.jpg'/></author><thr:total>0</thr:total></entry></feed>
